LONDON, June 22, 2021: Morgan Lewis has advised long-standing client Advanz Pharma on its agreement with Eisai Co., Ltd to acquire rights for the antiepileptic agent Zonegran (zonisamide) in the European Union, Middle East, Russia, and Australia.
London-based Advanz Pharma is a specialty pharmaceutical company that focuses on complex medicines in Europe. Under the agreement, Eisai will continue to act as the distributor in Russia and Australia, through its local affiliated companies, for an agreed transition period. In addition, Advanz Pharma and Eisai have agreed to enter into a supply agreement under which Eisai’s UK affiliate, Eisai Manufacturing Limited, will serve as Advanz Pharma’s supplier of Zonegran for the transferred territory for an agreed transition period.
Morgan Lewis partner Nick Moore and associate Humphrey Thomas represented Advanz Pharma.
For more, read Advanz Pharma’s announcement.